Cargando…
Therapeutic effects of TM4SF5-targeting chimeric and humanized monoclonal antibodies in hepatocellular and colon cancer models
The transmembrane 4 L six family member 5 (TM4SF5) is aberrantly expressed in hepatocellular and colorectal cancers, and has been implicated in tumor progression, suggesting that it could serve as a novel therapeutic target. Previously, we screened a murine antibody phage-display library to generate...
Autores principales: | Ko, Dongjoon, Kim, Eunmi, Shin, Eun-Ae, Nam, Seo Hee, Yoon, Junghwa, Lee, Jin-Sook, Lee, Yunhee, Park, Sora, Ha, Kyungsoo, Choi, So-Young, Lee, Jung Weon, Kim, Semi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8841960/ https://www.ncbi.nlm.nih.gov/pubmed/35211652 http://dx.doi.org/10.1016/j.omto.2022.01.006 |
Ejemplares similares
-
Anti-cancer Activity of Novel TM4SF5-Targeting Antibodies through TM4SF5 Neutralization and Immune Cell-Mediated Cytotoxicity
por: Ahn, Hye-Mi, et al.
Publicado: (2017) -
TMEM52B suppression promotes cancer cell survival and invasion through modulating E-cadherin stability and EGFR activity
por: Lee, Yunhee, et al.
Publicado: (2021) -
TM4SF5-mediated liver malignancy involves NK cell exhaustion-like phenotypes
por: Sun, Hyunseung, et al.
Publicado: (2021) -
TMPRSS4 promotes cancer stem–like properties in prostate cancer cells through upregulation of SOX2 by SLUG and TWIST1
por: Lee, Yunhee, et al.
Publicado: (2021) -
TM4SF5-Mediated Regulation of Hepatocyte Transporters during Metabolic Liver Diseases
por: Kim, Ji Eon, et al.
Publicado: (2022)